Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.